PolyPid (NASDAQ:PYPD – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $13.00 price objective on the stock. HC Wainwright‘s price objective points to a potential upside of 107.67% from the company’s previous close. HC Wainwright also issued estimates for PolyPid’s FY2029 earnings at $0.87 EPS and FY2030 earnings at $1.65 EPS.
Several other analysts also recently issued reports on PYPD. Craig Hallum set a $12.00 price target on PolyPid in a research note on Wednesday, July 22nd. Oppenheimer started coverage on PolyPid in a report on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. Finally, Wall Street Zen raised PolyPid from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.67.
View Our Latest Report on PolyPid
PolyPid Stock Down 2.2%
PolyPid (NASDAQ:PYPD – Get Free Report) last posted its earnings results on Wednesday, November 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.91 by ($1.15). The firm had revenue of $30.00 million during the quarter, compared to the consensus estimate of $30.00 million. As a group, research analysts expect that PolyPid will post -0.44 EPS for the current year.
Institutional Investors Weigh In On PolyPid
A number of large investors have recently bought and sold shares of the company. HighTower Advisors LLC increased its stake in PolyPid by 18.2% in the third quarter. HighTower Advisors LLC now owns 13,000 shares of the company’s stock valued at $69,000 after acquiring an additional 2,000 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its position in PolyPid by 32.7% during the third quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after purchasing an additional 4,955 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of PolyPid in the 2nd quarter valued at $87,000. Renaissance Technologies LLC acquired a new stake in shares of PolyPid in the 1st quarter valued at $81,000. Finally, Connective Capital Management LLC acquired a new stake in shares of PolyPid in the 2nd quarter valued at $343,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.
About PolyPid
PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.
See Also
- Five stocks we like better than PolyPid
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
